Compare · AIMD vs NVO
AIMD vs NVO
Side-by-side comparison of Ainos Inc. (AIMD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $228.39B, about 20250.9x AIMD ($11.3M).
- Over the past year, AIMD is down 47.5% and NVO is up 3.1% - NVO leads by 50.6 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for AIMD).
- NVO has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Ainos Inc.
- Novo Nordisk A/S
- Price
- $1.37-1.44%
- $51.58+1.25%
- Market cap
- $11.3M
- $228.39B
- 1M return
- -22.60%
- +6.72%
- 1Y return
- -47.51%
- +3.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AIMD
- SEC Form 424B5 filed by Ainos Inc.
- Ainos Expands Smell AI With Growing Real-World Scent Dataset for Physical AI
- Ainos Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Ainos Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence
- Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program
- Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
- Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
- Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
- VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S